Sana Biotechnology, Inc. (SANA) Bundle
A Brief History of SANA
SANA was founded in July 2018, focusing on engineered cell therapies with significant potential in treating various diseases. The company has emphasized developing hypoimmune-modified cells, which are designed to evade immune detection, thereby enhancing therapeutic efficacy. Over the years, SANA has invested heavily in its research and development efforts, aiming to revolutionize treatment options in areas with unmet medical needs.
Financial Overview as of 2024
As of September 30, 2024, SANA reported cash, cash equivalents, and marketable securities totaling $199.0 million. The company has raised approximately $1.5 billion in net proceeds from the issuance of common stock and private placements since its inception. Despite these efforts, SANA has incurred significant operating losses, with an accumulated deficit of $1.6 billion by the end of Q3 2024.
| Metrics | As of September 30, 2024 |
|---|---|
| Cash, Cash Equivalents, and Marketable Securities | $199.0 million |
| Accumulated Deficit | $1.6 billion |
| Total Net Proceeds Raised | $1.5 billion |
Recent Developments
In February 2024, SANA completed an underwritten public offering, selling 21.8 million shares of common stock, which included an additional 4.5 million shares from the underwriters' option. This offering generated net proceeds of approximately $180.0 million after deducting expenses.
Research and Development Expenditures
SANA has continued to invest heavily in research and development. For the nine months ended September 30, 2024, the company reported research and development-related success payments and contingent consideration totaling $4.6 million, a significant change from the prior year, where the figure was negative due to gains from previous evaluations.
| Research and Development Expenses | 2024 | 2023 |
|---|---|---|
| Cobalt Success Payment | $2.3 million | ($8.3 million) |
| Harvard Success Payments | ($0.008 million) | ($0.34 million) |
| Contingent Consideration | $2.25 million | ($47.23 million) |
| Total | $4.57 million | ($55.82 million) |
Market Position and Future Outlook
As of September 30, 2024, SANA's financial outlook remains cautious due to ongoing operating losses. The company has not yet generated revenue from product sales. Future funding requirements are anticipated as development progresses, particularly for clinical trials and potential commercialization of product candidates. The market remains competitive, with SANA focusing on strategic partnerships to enhance its research capabilities and expedite product development.
In November 2024, SANA announced a strategic repositioning, prioritizing clinical and preclinical development in key therapeutic areas, which may lead to significant operational changes, including a workforce reduction of approximately 45%.
| Strategic Repositioning Impact | Details |
|---|---|
| Workforce Reduction | Approximately 45% |
| Estimated Cash-based Expenses | $6.4 million |
| Focus Areas | Type 1 diabetes, B-cell mediated autoimmune diseases, refractory B-cell malignancies |
SANA's strategic decisions and financial maneuvers reflect an ongoing effort to stabilize its operations while navigating a complex and evolving biotechnology landscape. The future will depend on its ability to achieve clinical milestones and secure additional funding to support its ambitious goals.
A Who Owns Sana Biotechnology, Inc. (SANA)
Major Shareholders
As of 2024, the ownership structure of Sana Biotechnology, Inc. is characterized by a mix of institutional and insider holdings. The following table outlines significant shareholders and their respective ownership percentages:
| Shareholder | Ownership Percentage | Type of Ownership |
|---|---|---|
| BlackRock, Inc. | 15.5% | Institutional |
| The Vanguard Group, Inc. | 10.2% | Institutional |
| SSgA Funds Management, Inc. | 8.5% | Institutional |
| FMR LLC (Fidelity) | 6.7% | Institutional |
| Insider Ownership | 4.1% | Insider |
| Other Institutional Investors | 55.0% | Institutional |
Insider Holdings
Insider ownership is also a crucial aspect of the company's equity structure. Key executives and board members hold a combined total of approximately 4.1% of the company’s shares. This includes:
- CEO: 1.0%
- CFO: 0.8%
- Board Members: 2.3%
Recent Stock Performance
As of September 30, 2024, Sana Biotechnology's stock performance has been volatile, reflecting broader market trends and specific company developments. The stock price was approximately $4.50, down from $5.20 earlier in the year.
Financial Overview
As of September 30, 2024, Sana Biotechnology reported the following financial metrics:
| Financial Metric | Value |
|---|---|
| Cash and Cash Equivalents | $126.996 million |
| Marketable Securities | $72.011 million |
| Accumulated Deficit | $(1.555 billion) |
| Total Assets | $559.392 million |
| Total Liabilities | $266.914 million |
| Total Stockholders' Equity | $292.478 million |
Capital Raising Activities
In February 2024, Sana Biotechnology executed a public offering, selling 21.8 million shares for net proceeds of approximately $180 million. This capital is earmarked for research and development, as well as to support ongoing operational needs.
Market Capitalization and Future Outlook
The market capitalization of Sana Biotechnology as of September 30, 2024, was estimated at approximately $1.0 billion, reflecting investor sentiment and anticipated growth in the biopharmaceutical sector.
In summary, the ownership of Sana Biotechnology is predominantly held by institutional investors, with a smaller percentage owned by insiders. The company continues to navigate financial challenges while pursuing its strategic objectives in biotechnology.
Sana Biotechnology, Inc. (SANA) Mission Statement
Sana Biotechnology, Inc. focuses on harnessing the power of engineered cells to transform the treatment of diseases. The company aims to create and deliver innovative therapies by utilizing its proprietary ex vivo and in vivo cell engineering platforms. Sana's mission is centered around developing potentially curative therapies that can address unmet medical needs, particularly in the fields of cancer, autoimmune diseases, and genetic disorders.
Core Principles
- Innovation: Committed to advancing cell engineering technologies.
- Patient-Centricity: Focused on developing therapies that significantly improve patient outcomes.
- Collaboration: Engages in partnerships to enhance research and development efforts.
Financial Overview as of September 30, 2024
Sana Biotechnology has demonstrated significant financial movements in recent quarters. Below is a summary of key financial data:
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Net Loss | $59.9 million | $1.0 million | $(60.9 million) |
| Total Revenue | $0 | $0 | $0 |
| Research and Development Expenses | $170.5 million | $205.8 million | $(35.3 million) |
| General and Administrative Expenses | $14.1 million | $19.2 million | $(5.1 million) |
| Cash, Cash Equivalents, and Marketable Securities | $199.0 million | N/A | N/A |
Key Strategic Initiatives
As part of its mission, Sana is undertaking several strategic initiatives:
- Prioritizing clinical and preclinical development in type 1 diabetes and B-cell mediated autoimmune diseases.
- Suspending development of certain programs to focus resources on higher-potential projects.
- Establishing partnerships to leverage external expertise and resources.
Recent Developments
In February 2024, Sana completed an underwritten public offering, raising approximately $180 million to support its mission-driven initiatives . This funding is critical as the company has yet to generate any revenue from product sales since its inception. Additionally, as of September 30, 2024, Sana reported an accumulated deficit of $1.6 billion .
Future Outlook
The company anticipates continuing operational losses as it progresses through its research and development phases. Sana's existing cash and securities are projected to meet its operational needs for at least the next 12 months, although further financing will be necessary for future growth .
How Sana Biotechnology, Inc. (SANA) Works
Business Overview
Sana Biotechnology, Inc. focuses on developing engineered cell therapies using its proprietary ex vivo and in vivo cell engineering platforms. The company aims to create transformative medicines for patients with serious diseases.
Financial Performance
As of September 30, 2024, Sana reported a net loss of $217.7 million for the nine months ended September 30, compared to a net loss of $195.1 million for the same period in 2023. The accumulated deficit stood at $1.6 billion.
| Financial Metrics | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Net Loss | $217.7 million | $195.1 million |
| Accumulated Deficit | $1.6 billion | $1.3 billion |
Research and Development Expenses
Research and development expenses for the nine months ended September 30, 2024, amounted to $170.5 million, down from $205.8 million in the same period of 2023. The decline was attributed to decreased personnel and lower manufacturing costs.
| Expense Categories | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Research and Laboratory | $23.1 million | $39.5 million |
| Personnel | $71.9 million | $87.1 million |
| Third-party Manufacturing | $6.9 million | $15.2 million |
| Clinical Development | $16.9 million | $7.9 million |
| Total R&D Expense | $170.5 million | $205.8 million |
Cash Flow and Liquidity
As of September 30, 2024, Sana had cash, cash equivalents, and marketable securities of $199.0 million. The company expects this will be sufficient to cover its operational needs for at least the next 12 months.
| Cash Flow Activities | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Operating Activities | ($175.99 million) | ($201.62 million) |
| Investing Activities | ($29.64 million) | $156.70 million |
| Financing Activities | $199.11 million | $29.93 million |
Capital Raising Activities
In February 2024, Sana completed an underwritten public offering, selling 21.8 million shares for net proceeds of approximately $180.0 million. Additionally, under an ATM facility, the company raised $28.6 million by selling 4.9 million shares as of September 30, 2024.
Contractual Obligations
As of September 30, 2024, Sana's significant contractual obligations are summarized below:
| Payment Due by Period | Less than 1 Year | 1 to 3 Years | 3 to 5 Years | More than 5 Years | Total |
|---|---|---|---|---|---|
| Operating Lease Obligations | $19.85 million | $43.16 million | $30.49 million | $82.93 million | $176.43 million |
Future Funding Requirements
Sana anticipates needing additional funding to support ongoing research and development efforts, including clinical trials and establishing manufacturing capabilities. The company may seek to raise capital through equity or debt financing as needed.
Key Partnerships and Collaborations
Sana has entered into various strategic agreements, including those with Cowen and Company for market offerings, and has engaged in collaborations aimed at enhancing its research capabilities.
Stock Performance
The stock performance of Sana Biotechnology has been volatile. As of September 30, 2024, the company had issued 223.1 million shares of common stock. The stock price has fluctuated significantly due to market conditions and company developments.
How Sana Biotechnology, Inc. (SANA) Makes Money
Business Model Overview
Sana Biotechnology, Inc. operates primarily in the field of cell engineering and biotechnology. The company focuses on developing product candidates that utilize its proprietary ex vivo and in vivo cell engineering platforms. As of 2024, Sana has not yet commercialized any products and has been relying on funding through equity offerings and other financing methods.
Revenue Generation Strategies
Currently, Sana Biotechnology does not generate revenue from product sales. Instead, it raises capital through various financing activities, including:
- Public offerings of common stock
- At-the-market (ATM) equity offerings
- Potential licensing agreements and collaborations
Financial Performance
As of September 30, 2024, Sana Biotechnology reported a net loss of $217.7 million and an accumulated deficit of $1.6 billion since its inception. The financial performance highlights the company's ongoing investments in research and development without corresponding revenue generation.
Recent Equity Offerings
In February 2024, Sana completed an underwritten public offering, selling 21.8 million shares of common stock, including 4.5 million shares from the underwriters' option to purchase additional shares, resulting in net proceeds of approximately $180 million after expenses. Additionally, from its ATM facility established in August 2022, the company has raised $28.6 million as of September 30, 2024.
Expenses Breakdown
For the nine months ended September 30, 2024, Sana incurred the following operating expenses:
| Expense Type | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) |
|---|---|---|---|
| Research and Development | $170,528 | $205,823 | $(35,295) |
| General and Administrative | $46,763 | $52,515 | $(5,752) |
| Total Operating Expenses | $221,857 | $202,522 | $19,335 |
Research and Development Focus
Sana's primary expenditure is on research and development, which accounted for over 76% of total operating expenses in 2024. This focus is essential for developing its cell engineering technologies, which are still in the preclinical and clinical trial stages.
Cash and Marketable Securities
As of September 30, 2024, Sana had cash, cash equivalents, and marketable securities totaling $199.0 million, providing a financial cushion to support ongoing operations and R&D activities.
Future Funding Requirements
To sustain its operations and ongoing research, Sana will need to continue raising capital through equity offerings or strategic collaborations, as it does not expect to generate revenue from product sales in the near future. The company has indicated a need for additional funding to cover operational costs, clinical trials, and potential commercialization efforts in the coming years.
Strategic Repositioning
In November 2024, Sana announced a strategic repositioning to focus on specific therapeutic areas, which may result in reduced operating expenses going forward. This includes a workforce reduction and a shift in R&D priorities.
Sana Biotechnology, Inc. (SANA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Sana Biotechnology, Inc. (SANA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Sana Biotechnology, Inc. (SANA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Sana Biotechnology, Inc. (SANA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.